3 Stocks Moving The Drugs Industry Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 36 points (0.2%) at 17,520 as of Thursday, Nov. 6, 2014, 12:00 PM ET. The NYSE advances/declines ratio sits at 1,530 issues advancing vs. 1,416 declining with 183 unchanged.

The Drugs industry currently sits down 0.2% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Alexion Pharmaceuticals ( ALXN), up 2.8%, Actavis ( ACT), up 1.9%, Grifols ( GRFS), up 1.9%, Regeneron Pharmaceuticals ( REGN), up 1.3% and Bristol-Myers Squibb Company ( BMY), up 1.2%. On the negative front, top decliners within the industry include Epizyme ( EPZM), down 19.8%, Seattle Genetics ( SGEN), down 4.8%, Valeant Pharmaceuticals International ( VRX), down 1.8% and AstraZeneca ( AZN), down 1.1%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Jazz Pharmaceuticals ( JAZZ) is one of the companies pushing the Drugs industry higher today. As of noon trading, Jazz Pharmaceuticals is up $3.74 (2.2%) to $170.92 on light volume. Thus far, 282,832 shares of Jazz Pharmaceuticals exchanged hands as compared to its average daily volume of 842,600 shares. The stock has ranged in price between $167.03-$171.98 after having opened the day at $170.04 as compared to the previous trading day's close of $167.18.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Jazz Pharmaceuticals has a market cap of $10.1 billion and is part of the health care sector. Shares are up 32.1% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Jazz Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and premium valuation. Get the full Jazz Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Vertex Pharmaceuticals ( VRTX) is up $4.67 (4.2%) to $116.26 on light volume. Thus far, 594,212 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $111.85-$116.85 after having opened the day at $112.43 as compared to the previous trading day's close of $111.59.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. Vertex Pharmaceuticals has a market cap of $27.2 billion and is part of the health care sector. Shares are up 50.2% year-to-date as of the close of trading on Wednesday. Currently there are 9 analysts who rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, unimpressive growth in net income and disappointing return on equity. Get the full Vertex Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Biogen Idec ( BIIB) is up $3.00 (0.9%) to $322.55 on average volume. Thus far, 516,028 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $320.27-$324.00 after having opened the day at $320.86 as compared to the previous trading day's close of $319.55.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $76.1 billion and is part of the health care sector. Shares are up 14.3% year-to-date as of the close of trading on Wednesday. Currently there are 12 analysts who rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts

Facebook, Amazon, Microsoft and Ford - 5 Things You Must Know

Facebook, Amazon, Microsoft and Ford - 5 Things You Must Know

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment

Let the Najarian Brothers Help You Generate Income With Options

Let the Najarian Brothers Help You Generate Income With Options